Vito Levi D’Ancona is an Italian‑born American entrepreneur with extensive international experience across Europe, Asia, and the United States. Trained as a mechanical engineer (University of Florence) and later in entrepreneurship (London Business School), he has spent two decades founding and leading deep‑tech companies in biotechnology, communications, and personal security.
Since 2022, he has served as founding President of Nemdx Inc., driving the development of novel molecular binding for neurodegeneration. His work focuses on defining strategic aims, guiding scientific and commercial teams, and advancing innovative approaches to unmet clinical needs—particularly the creation of a reliable biomarker test for ALS.
He is also founding director of Scientific Venture Partner Ltd, Mantacus Inc., founding chairman of Bellantenna Inc. and Qbiotix Ltd, and advisor to 2020 Healthcare Partners. From 2006 to 2020, he was a principal at Anglo Scientific, co‑founding multiple technology companies, several of which were successfully acquired. He previously served as President of Mrt Laboratories Inc., a CLIA/CAP‑accredited clinical laboratory, which was ultimately sold to another lab.
Across his career, Mr Levi D’Ancona has built and scaled ventures, overseen technology commercialization, and led multidisciplinary teams to deliver high‑impact solutions in diagnostics and advanced engineering.
Vito Levi D’Ancona is an Italian‑born American entrepreneur with extensive international experience across Europe, Asia, and the United States. Trained as a mechanical engineer (University of Florence) and later in entrepreneurship (London Business School), he has spent two decades founding and leading deep‑tech companies in biotechnology, communications, and personal security.
Since 2022, he has served as founding President of Nemdx Inc., driving the development of novel molecular binding for neurodegeneration. His work focuses on defining strategic aims, guiding scientific and commercial teams, and advancing innovative approaches to unmet clinical needs—particularly the creation of a reliable biomarker test for ALS.
He is also founding director of Scientific Venture Partner Ltd, Mantacus Inc., founding chairman of Bellantenna Inc. and Qbiotix Ltd, and advisor to 2020 Healthcare Partners. From 2006 to 2020, he was a principal at Anglo Scientific, co‑founding multiple technology companies, several of which were successfully acquired. He previously served as President of Mrt Laboratories Inc., a CLIA/CAP‑accredited clinical laboratory, which was ultimately sold to another lab.
Across his career, Mr Levi D’Ancona has built and scaled ventures, overseen technology commercialization, and led multidisciplinary teams to deliver high‑impact solutions in diagnostics and advanced engineering.